Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
Status:
Terminated
Trial end date:
2019-12-18
Target enrollment:
Participant gender:
Summary
18F Fluciclovine is a recently FDA- approved radiopharmaceutical for prostate cancer
biochemical recurrence, which is only minimally eliminated by the kidneys and therefore the
image interpretation is not affected by nonspecific urine activity in the ureters and
bladder, which is advantageous for pelvic imaging. Recent literature suggests that
Fluciclovine PET has diagnostic potential for a variety of solid tumors, thus, allowing new
opportunities for noninvasive probing of glutamine metabolism and clinical use in patient
management. Current literature indicates that amino acid transporters including that of
glutamine are upregulated in endometrial and cervical cancer so that Fluciclovine PET may
have clinical potentials. The hypothesis is that Fluciclovine PET provides better imaging
properties and greater diagnostic confidence and accuracy than FDG PET does in pelvic
malignancies.
Given the lack of current clinical data, a pilot study providing a direct comparison of
Fluciclovine PET with FDG PET is warranted. The investigators seek to conduct a pilot study
with 10 subjects to evaluate the clinical utility of Fluciclovine PET for staging of cervical
cancer and endometrial cancer. This research will compare the diagnostic performance of the
research Fluciclovine PET/MRI with the standard-of-care FDG PET/CT as an exploratory
endpoint.